Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · April 08, 2024

Prognostic Value of ctDNA in Patients With Relapsed/Refractory Multiple Myeloma Receiving Ixazomib, Lenalidomide, and Dexamethasone

Blood

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

Blood
ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone
Blood 2024 Mar 01;[EPub Ahead of Print], Y Kogure, H Handa, Y Ito, M Ri, Y Horigome, M Iino, Y Harazaki, T Kobayashi, M Abe, T Ishida, S Ito, H Iwasaki, J Kuroda, H Shibayama, K Sunami, H Takamatsu, H Tamura, T Hayashi, K Akagi, T Shinozaki, T Yoshida, I Mori, S Iida, T Maeda, K Kataoka

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated